{"organizations": [], "uuid": "63d4c5f152e31383a13d2aab9af6fc590d01ad31", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/hikma-pharma-outlook/update-1-hikma-reaffirms-full-year-revenue-forecast-cites-better-generics-business-idUSL3N1SP2N3", "country": "US", "domain_rank": 408, "title": "UPDATE 1-Hikma reaffirms full-year revenue forecast, cites better generics business", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-18T10:32:00.000+03:00", "replies_count": 0, "uuid": "63d4c5f152e31383a13d2aab9af6fc590d01ad31"}, "author": "", "url": "https://www.reuters.com/article/hikma-pharma-outlook/update-1-hikma-reaffirms-full-year-revenue-forecast-cites-better-generics-business-idUSL3N1SP2N3", "ord_in_thread": 0, "title": "UPDATE 1-Hikma reaffirms full-year revenue forecast, cites better generics business", "locations": [], "entities": {"persons": [{"name": "sigurdur olafsson", "sentiment": "none"}, {"name": "hikma", "sentiment": "none"}], "locations": [{"name": "advair", "sentiment": "none"}, {"name": "united states", "sentiment": "none"}], "organizations": [{"name": "glaxosmithkline", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "teva pharmaceuticals", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "hikma pharmaceuticals plc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 18, 2018 / 7:34 AM / Updated 8 minutes ago UPDATE 1-Hikma reaffirms full-year revenue forecast, cites better generics business Reuters Staff 2 Min Read\n(Adds details on quarter, context, comments on Advair launch and share price)\nMay 18 (Reuters) - Hikma Pharmaceuticals Plc on Friday reaffirmed its revenue guidance for the full year, noting its generics business was performing better due to a favourable product mix, despite continued pricing pressure in the United States.\nShares of the company were up as much as 4 percent at the market open before settling up 0.7 percent at 0725 GMT.\nThe drugmaker, which was forced to cut revenue guidance for its generics business three times in 2017, said it continued to expect revenue from the business to be between $550 million and $600 million in 2018.\nSigurdur Olafsson, former generics chief at drug giant Teva Pharmaceuticals, was named Hikma’s chief executive officer in February.\nThe company suffered a setback in March for its generic version of GlaxoSmithKline’s blockbuster lung drug Advair, after the U.S. Food and Drug Administration asked Hikma to conduct a further clinical study evaluating the drug, dashing hopes to get it to the market this year.\n“The study is proceeding as planned and we expect to submit a response to the FDA with the new clinical data as early as possible in 2019”, the company said on Friday. (Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr)", "external_links": [], "published": "2018-05-18T10:32:00.000+03:00", "crawled": "2018-05-18T10:47:30.034+03:00", "highlightTitle": ""}